Comparison of the function of two novel human dopamine D2 receptor variants identifies a likely mechanism for their pathogenicity

• Published in: Biochemical pharmacology 2024-10, Vol.228, p.116228, Article 116228
• Main Authors: Rodriguez-Contreras, Dayana, García-Nafría, Javier, Chan, Amy E, Shinde, Ujwal, Neve, Kim A.
• Format: Article
• Language: English
• Subjects: Adenylate cyclase; Animals; Arrestin; Constitutive activation; Dopamine Agonists - pharmacology; Dopamine receptor; HEK293 Cells; heterotrimeric G protein; Humans; Movement disorder; Mutation; Receptors, Dopamine D2 - genetics; Receptors, Dopamine D2 - metabolism
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2024.116228

[Display omitted] Two recently discovered DRD2 mutations, c.634A > T, p.Ile212Phe and c.1121T > G, p.Met374Arg, cause hyperkinetic movement disorders that have overlapping features but apparently differ in severity. The two known carriers of the Met374Arg variant had early childhood disease onset and more severe motor, cognitive, and neuropsychiatric deficits than any known carriers of the Ile212Phe variant, whose symptoms were first apparent in adolescence. Here, we evaluated if differences in the function of the two variants in cultured cells could explain differing pathogenicity. Both variants were expressed less abundantly than the wild type receptor and exhibited loss of agonist-induced arrestin binding, but differences in expression and arrestin binding between the variants were minor. Basal and agonist-induced activation of heterotrimeric Gi/o/z proteins, however, showed clear differences; agonists were generally more potent at Met374Arg than at the Ile212Phe or wild type variants. Furthermore, all Gα subtypes tested were constitutively activated more by Met374Arg than by Ile212Phe. Met374Arg produced greater constitutive inhibition of cyclic AMP accumulation than Ile212Phe or the wild type D2 receptor. Met374Arg and Ile212Phe were more sensitive to thermal inactivation than the wild type D2 receptor, as reported for other constitutively active receptors, but Ile212Phe was affected more than Met374Arg. Additional pharmacological characterization suggested that the mutations differentially affect the shape of the agonist binding pocket and the potency of dopamine, norepinephrine, and tyramine. Molecular dynamics simulations provided a structural rationale for enhanced constitutive activation and agonist potency. Enhanced constitutive and agonist-induced G protein-mediated signaling likely contributes to the pathogenicity of these novel variants.